Table 2 PVT1 expression and clinical characteristics in patients with hyperparathyroidism
From: Role of LncRNA score and PVT1 in primary hyperparathyroidism-- a preliminary study
Clinical characteristics | Low-PVT1 (n = 29) | High-PVT1 (n = 28) | P-value | |
|---|---|---|---|---|
Age (SD)(years) | 59.4 (13.4) | 57.1 (12.6) | 0.500 | |
Sex (% M) | 31.0 | 39.3 | 0.585 | |
Disease course (SD) (month) | 64.2 (92.3) | 78.7 (96.6) | 0.576 | |
Cause of first diagnosis (%) | With any discomfort | 48.3 | 78.6 | 0.028# |
discomfort in Bone system | 31.0 | 35.7 | 0.783 | |
Nephrolith | 13.8 | 17.9 | 0.730 | |
Discomfort in Digestive system | 6.9 | 7.1 | 1.000 | |
Thyroid nodular | 17.2 | 7.1 | 0.423 | |
Elevated Ca2+ level | 24.1 | 25.0 | 1.000 | |
Clinical manifestation (%) | Bone system | 62.1 | 71.4 | 0.576 |
Nephrolith | 48.3 | 32.1 | 0.283 | |
Digestive system | 17.2 | 39.3 | 0.082 | |
Laboratory examination | iPTH (SD) (pg/mL) | 442.2 (482.3) | 713.0 (690.5) | 0.091 |
Ca2+(SD) (mmol/L) | 2.76 (0.33) | 2.97 (0.42) | 0.036* | |
Albumin adjusted Ca2+(SD)(mmol/L) | 2.73 (0.36) | 2.98 (0.42) | 0.021* | |
P (SD)(mmol/L) | 0.88 (0.43) | 0.79 (0.33) | 0.370 | |
ALP (SD) (U/L) | 144.0 (223.3) | 218.0 (297.9) | 0.292 | |
Imaging location consistent with histopathology (%, n) | Tc-99 m-MIBI | 88.9 (18) | 77.8 (18) | 0.658 |
Contrast enhanced CT | 64.3 (14) | 70.00 (10) | 1.000 | |
Thyroid ultrasound | 70.8 (24) | 72.2 (18) | 1.000 | |
Histopathology | Maximum diameter (SD) (cm) | 2.01 (1.34) | 2.58 (1.24) | 0.103 |
parathyroid cancer (%) | 0 | 39.3 | 0.000# | |
LncRNA score (SD) | 37.8 (8.9) | 62.0 (46.9) | 0.008* | |